PET-CT and MR Imaging in the Management of Axillary Nodes in Early Stage Breast Cancer

Mehmet Tarik Baran¹, Hasan Gundogdu², Gokhan Demiral¹, Osman Kupik³, Medeni Arpa⁴ and Ahmet Pergel¹

¹Department of General Surgery, Recep Tayyip Erdogan University, Rize, Turkey

²Department of Radiology, Recep Tayyip Erdogan University, Rize, Turkey

³Department of Nuclear Medicine, Recep Tayyip Erdogan University, Rize, Turkey

⁴Department of Biochemistry, Recep Tayyip Erdogan University, Rize, Turkey

ABSTRACT

Objective: To discriminate between malignant or benign axillary lymph nodes in breast cancer using MRI, PET-CT, and sentinel lymph node biopsy.

Study Design: Observational study.

Place and Duration of Study: Department of General Surgery, Recep Tayyip Erdogan University School of Medicine, from January 2014 to March 2019.

Methodology: Sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) was carried out on 102 patients, who had locally advanced cases and had not previously received neoadjuvant therapy. Axillary lymph nodes pathology results were evaluated and compared with PET-CT and MRI findings.

Results: PET-CT specificity was 93.18%, MRI specificity was 93.75%, and combined PET-CT and MRI specificity was 97.67%. PET-CT sensitivity was 81.03%, MRI sensitivity was 68.57%, and combined PET-CT and MRI sensitivity was 83.05%. For detecting the presence of axillary lymph node metastasis, there was a good correlation between histopathological results and the combined evaluation with PET-CT and MRI (kappa: 0.785, $p < 0.001$). In combined PET-CT and MRI, short diameter mean values of lymph nodes in 10 patients, which could not detect lymph node metastases, were determined to be 5.2 ± 0.9 mm.

Conclusion: Combining PET-CT and MRI is superior to PET-CT or MRI imaging alone in distinguishing benign and malignant axillary lymph node; and contributes to deciding the approach to axillary lymph node surgery. Lymph node size is also important for this imaging method to determine benign and malignant nodes correctly.

Key Words: Breast cancer, PET-CT, MRI, Sentinel lymph node biopsy, Axilla.

How to cite this article: Baran MT, Gundogdu H, Demiral G, Kupik O, Arpa M, Pergel A. PET-CT and MR Imaging in the Management of Axillary Nodes in Early Stage Breast Cancer. *J Coll Physicians Surg Pak* 2020; **30(09)**:946-950.

INTRODUCTION

Breast cancer is the second most frequently diagnosed malignancy in the world after lung cancer; and more than two million new cases are seen each year.¹ It is the leading cause of death in women around the world.²

The most important factors determining the prognosis are: tumour size, histological grade, hormonal receptor status, human epidermal growth factor receptor 2 (HER-2) status, axillary lymph node involvement, and metastasis.

Axillary lymph node involvement is very important in terms of prognosis, staging, and treatment planning to be selected for the management of the disease.

The examination to be performed after staging, the treatment modalities to be applied, and the management of the patients were determined in detail by National Comprehensive Cancer Network (NCCN).³

Surgeries are performed specifically for the mass in the breast and for the axilla, depending on the condition of the axillary lymph nodes. Axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB) is performed according to the condition of the axilla. In patients undergoing sentinel lymph node sampling during surgery, it is to be determined whether or not there will be an intervention to the axilla.⁴ Serious morbid complications, such as lymphedema of the arm, may occur after surgery or local radiotherapy to the axilla.⁵ In order to establish a good preoperative decision, the objective of this study was to discriminate between malignant or benign axillary lymph nodes in breast cancer using MRI, PET-CT, and sentinel lymph node biopsy.

METHODOLOGY

A total of 102 patients, diagnosed with locally advanced breast cancer between March 2014 and January 2019 at General

Correspondence to: Dr. Mehmet Tarik Baran, Department of General Surgery, Recep Tayyip Erdogan University, Rize, Turkey
E-mail: mehmettarik.baran@erdogan.edu.tr

Received: June 12, 2020; Revised: September 18, 2020;
Accepted: September 18, 2020
DOI: <https://doi.org/10.29271/jcpsp.2020.09.946>

Surgery Clinic, Recep Tayyip Erdogan University School of Medicine, were retrospectively evaluated after the approval by the Clinical Research Ethics Committee. Those patients were included in the study, who were newly diagnosed, underwent 3-Tesla MRI as well as 18F FDG labelled PET-CT, did not receive neoadjuvant therapy, and had undergone SLNB and/or ALND. Exclusion criteria were patients with metastasis, who had PET-CT and MRI performed at the external centre, under the age of 18 years, and with distortion or artefacts on MRI scan.

PET-CT and MRI were retrospectively reassessed by radiology specialist and nuclear medicine specialist, respectively. Clinical information, pathology results, previous imaging reports, and surgical findings were not shared with them.

MRI was performed on 3-Tesla MRI (Discovery w750, GE Healthcare, United States). Contrast agent was injected intravenously following pre-contrast images. Then dynamic imaging was performed. Diffusion-weighted images were taken without contrast, and the axial plane was obtained by applying a gradient sensitising diffusion at different b values (50 sec/mm², 800 sec/mm²) in three directions (x, y, z).

Tumour characteristics, including the largest dimension, shape, location, and contrast enhancement of primary tumour, were evaluated. To distinguish positive and negative axillary lymph nodes, the diameter of the short axillary lymph node (LnD), short/long axis ratio, asymmetric cortex, indeterminate margins, absence of fatty hilum perinodular oedema, cortical thickness increase, diffusion-weighted imaging, and visual examination of ADC were performed with ADC values (Figures 1a, 1b). Images were uploaded on PACS (picture archiving and communication system).

PET-CT imaging was performed with biograph mCT (Siemens Healthcare, Erlangen, Germany) scanner. Siemens Healthineers Syngo via VB30 workstation, MM oncology and post-processing unit was used in the analysis. The short-axis diameter of the axillary lymph nodes was measured. Maximum standard uptake value (SUVmax) was measured from the most prominent FDG avid lymph node (Figure 1c). Blood pool SUVmax was measured from the aortic arch. As axillary lymph node metastasis criterion, the SUVmax value measured from the lymph node was considered to be higher than the blood pool SUVmax value measured from the aorta.

The mean gap between MRI and axillary surgery was 11 (2: 29) days; and 09 (3: 22) days for PET-CT.

Periareolar region was stained with isosulfan blue, massaged for 15 minutes. Then, the stained first lymph node with the axillary incision was excised and sent to pathology to make for the frozen sentinel section. Sentinel lymph node sampling with isosulfan blue is a method preferred at the study centre because it is easily accessible, cheaper, and its sensitivity is higher than radioisotope sentinel sampling in some studies.⁶ Although isosulfan blue and radioisotope sentinel lymph node sampling together gave more surgical confidence, in this study, isosulfan blue alone was the preferred method.

Research data were uploaded and evaluated via SPSS (Statistical Package for Social Sciences) for Windows 20.0 (SPSS Inc, Chicago, IL). Descriptive statistics were presented as mean $\pm$ SD frequency distribution, and percentage. Diagnosis performances of MRI and PET-CT were evaluated by accepting the pathology as the gold standard. Sensitivity, specificity, PPV, NPV and accuracy rates were determined. The coherence between MRI, 18F-FDG PET-CT, and pathology was evaluated by kappa analysis. Significance level was accepted as $p < 0.05$.

RESULTS

A total of 102 patients, histopathologically diagnosed with breast cancer, were scanned with 18-F FDG PET-CT and MRI before treatment. Their average age was 55.4 ± 12.78 years. Fifty-three (52%) of the patients had cancer in their left breast, and 49 (48%) had the cancer in the right breast. Eighty-eight (86.3%) of all these patients were luminal; 6 (5.9%) were HER-2 positive, and 8 (7.8%) were triple negative. ALND was performed in 70 (68.6%) patients included in the study. Of these patients, 46 (45.1%) patients with clinically and radiologically positive axilla directly had axillary dissection. SLNB was performed in 56 (54.9%) patients, who were clinically and radiologically negative. Depending on their state, axillary dissection with SLNB was performed to 24 (23.5%) of these patients. The sentinel lymph node was not stained with isosulfan blue in 9 (8.8%) patients who underwent ALND; lymph node metastasis was not detected on pathology. Two patients had lymph node metastasis and one patient was negative after ALND pathology results. MRI and PET-CT results were negative in 2 (2.0%) of the patients who were found to be positive. The axillary intervention and sentinel results are given in detail in Table I.

There were 3 (2.9%) patients who had negative sentinel lymph nodes, but underwent axillary dissection due to non-sentinel palpable lymph nodes. As a result of ALND, axilla positive in two patients and negative pathology in one patient. PET-CT was positive in one and negative in one of two axilla-metastatic patients. MRI reported all three patients as negative.

Axillary dissection was performed in all 9 (8.8%) patients with a positive sentinel lymph node. When the MRI and PET-CTs of these patients were evaluated retrospectively, PET-CT was considered to be positive in three patients; whereas, in MRI, axilla was positive in one patient and negative in others. In the pathology report of three of nine SLNB positive patients, metastasis was detected only in one lymph node.

The result of axilla pathology was positive in 53 (52%) patients and negative in 49 (48%) patients. Histopathologically, 52 patients had metastases; and PET-CT could not detect axillary lymph nodes in 11 (21.2%) patients. Histopathologically, 50 patients, who did not have metastases, did not have PET-CT axillary lymph node metastasis in 47 (94%, kappa 0.726, $p < 0.001$). The data are shown in detail in Table II.

Histopathologically, 52 patients had metastases, and MRI could not detect axillary lymph node in 22 (42.3%) patients, kappa 0.533, $p < 0.001$).

Table I: Classification of patients undergoing SLNB and ALND (n: 102).

Axillary interventions	Sentinel negative	Sentinel positive	Sentinel suspicious	Sentinel lymph node not found
SLNB+ALND	3 (2.9%)*	9 (8.8%)	3 (2.9%)	9 (8.8%)
SLNB alone	32 (31.4%)			
ALND alone	46 (45.1%)			

*ALND was performed because there was non-sentinel (+) and malignant suspicious lymph nodes founded.

Table II: Cross-tabulation of 18F- FDG PET-CT and pathology result (n: 102).

Pathological axilla status	PET-CT no axillary metastasis	PET-CT axillary metastasis present	Total
No axillary metastasis	47 (94%)	3 (6%)	50 (100%)
Axilla metastasis present	11 (21.2%)	41(78.8%)	52 (100%)
Total	58 (56.9%)	44 (43.1%)	102 (100%)

Table III: Cross-tabulation of MRI and pathology result (n: 102).

Pathological axilla status	MR no axillary metastasis	MR axillary metastasis present	Total
No axillary metastasis	48 (96%)	2 (4%)	50 (100%)
Axilla metastasis present	22 (42.3%)	30 (57.7%)	52 (100%)
Total	70 (68.6%)	32 (31.4%)	102 (100%)

Table IV: Sensitivity, specificity, accuracy, positive predictive value, negative predictive value were given by MRI alone, 18F- FDG PET-CT alone, and MRI and 18F-FDG PET-CT together (n: 102).

Parameters	18F- FDG PET-CT	MRI	18F- FDG PET-CT + MRI
Sensitivity	81.03%	68.57%	83.05
Specificity	93.18%	93.75%	97.67%
Positive likelihood rate	11.89	10.97	35.71
Negative likelihood rate	0.20	0.34	0.2
Positive predictive value	94%	96%	98%
Negative predictive value	78.85%	57.69%	80.77%
Accuracy	86.27%	76.47%	89.22%

Figure 1: (a) Mass lesion in the left breast with pathological contrast involvement in contrast-enhanced MRI examination (red arrow); and pathological lymph node in the left axilla (white arrow). (b) Diffusion-weighted MRI of left axillary lymph node (white arrow). The lymph node in Figure 1a has a low ADC value. (c) Significant 18F-FDG uptake of the same lymph node is observed in PET-CT.

PET-CT and MRI together detected the presence of metastases in 42 (80.8%) of 52 patients. Forty-nine (98%) of 50 non-metastatic patients were detected (kappa 0.785, $p < 0.001$). A good coherence between the total result of MRI and PET-CT visual evaluation and histopathological results was found. The accuracy and likelihood values are given in Table IV.

When 18F-FDG PET-CT and MRI were evaluated together, the short diameter mean values of lymph nodes PET-CT and MRI were found to be $5.2 \text{ mm} \pm 0.9 \text{ mm}$ and $6.5 \pm 0.85 \text{ mm}$, respectively; in 10 patients, where the presence of lymph node metastases could not be detected.

DISCUSSION

In the management of breast cancer, axillary lymph node involvement is a guide to the prognosis, staging, and treat-

ment planning. Clear determination of the malignant or benign status of the axillary lymph nodes, with the help of radiological imaging, ensures correct staging.⁷ Successful staging affects prognosis and survival by ensuring the correct treatment plan. In the study by Arriagada *et al.*, four factors were associated with the risk of death. These were tumor size, histological grade, involved axillary lymph node number, and age of diagnosis.⁸ In this study, PET-CT, MRI, sentinel lymph node sampling, and histopathology methods were used to determine involvement of lymph nodes. In this way, it was aimed to identify the method with less intervention in the axillary region and to show the accuracy of radiological methods to the management of breast cancer surgery.

Apart from screening and diagnosis, imaging is an important guide in clarifying staging. In this context, Breast ultrasound and breast MR are recommended for diagnostic purposes, based on screening mammography by NCCN. There are many different imaging modalities for diagnosis and staging purposes. There are many studies such as PET-CT, MRI, USG or combinations of these for the selection of axilla surgery for axilla.⁹⁻¹³

As in this study, there are few studies that PET-CT and MRI are together in the literature.¹⁴ In this study, patients who underwent 18F-FDG PET-CT and MRI to determine the breast lesion were preferred for axillary staging.

In study by McDonough *et al.*, comparing with other similar studies, it was revealed that the number and size of axillary

lymph node involvement were important criteria in determining axillary metastasis with PET-CT. Considering all the studies of PET-CT, its sensitivity was in the range of 79%-100%, and specificity was between 66-100%.¹⁵ In the present study, PET-CT sensitivity was 81.03%, specificity was 93.18%; and similar results were found with previous studies. Although PET-CT is very successful in axillary staging, some studies have shown that PET-CT cannot replace ALND and SLNB.¹⁶

McDonough *et al.* compared some studies and reported that only one lymph node involvement was observed in 25% of patients with sentinel lymph node micro-metastasis. If an appropriate technique is used to determine micro-metastases, it is thought that the need for sentinel lymph node sampling and axillary dissection may decrease; and the patient will be exposed to less morbid complications.¹⁵ In this study, only one positive lymph node involvement was observed in three out of nine cases, 33.3% of which were sentinel lymph node positive. According to the ACOSOG Z0011 study, ALND and radiotherapy have been shown to have the same survival results in patients with early-stage clinically axilla negative and SLNB and 1-2 metastatic sentinel lymph nodes. In the future, imaging methods have become more important for unnecessary SLNB.^{17,18}

In the first studies on PET-CT in breast cancer diagnosis and staging, its accuracy has been shown to vary, depending on the size of the tumour and the diameter of the axillary lymph node. It was more difficult to detect positive lymph nodes in lymph nodes less than 1 cm in diameter. Lesions that are not palpable and cannot be clearly identified by other imaging modalities are detected by PET-CT.¹⁹ Similarly, PET-CT and MRI accuracy rate was found to be increased according to the lymph node diameter in this study.

Kvistad *et al.* have been shown to be able to display lymph nodes better with dynamic MRI, but the number of false negatives was not negligible. Sensitivity was 83%, and specificity was 90%.²⁰ Comparing with our study, in this study the sensitivity in evaluating the axillary lymph nodes was found to be 68.57%, and the specificity was 93.75%.

In the study by An *et al.*, the sensitivity of MRI alone was found to be 67.5%, and the specificity was 78%. The sensitivity of PET-CT alone was 62.7%, and the specificity was 88.6%. The sensitivity of the association of both imaging methods was 72.3% and the specificity was 92.4%. In the diagnosis and evaluation of axillary lymph nodes, it was seen that the evaluation of imaging modalities together increased accuracy rates, sensitivity, specificity, and predictive value.⁹ Overlapping with this work, the sensitivity and specificity of PET-CT and MRI alone were lower than the sensitivity and specificity with which they were evaluated rather than evaluating alone. Evaluating both the imaging methods together gave clearer and more accurate results.

The main limitations of this study was a single centre, and retrospective analysis. The authors believe that with the development of imaging methods and wider study results, axillary intervention rates will decrease. When PET-CT and MRI are used together, the contribution of the axilla to the surgical management will become clearer with the studies with more participation in the future.

CONCLUSION

In axillary management, evaluating with both 18F-FDG PET-CT and MRI together yielded higher sensitivity and specificity than evaluating them alone in patients with early-stage breast cancer. Compared with ALND and SLNB, it suggests that these imaging methods can be non-invasive complementary methods with their diagnostic performance. 18-FDG PET-CT and MRI are good diagnostic methods for surgical selection in the approach to axilla; but both imaging methods cannot replace SLNB in making ALND decisions in axilla clinically negative patients.

ETHICAL APPROVAL:

This study was conducted at General Surgery Clinic, Recep Tayyip Erdogan University School of Medicine after the approval by the Clinical Research Ethics Committee.

PATIENTS' CONSENT:

Informed consents were obtained from all the patients prior conducting the study.

CONFLICT OF INTEREST:

The authors declared no conflict of interest.

AUTHORS' CONTRIBUTION:

MTB, AP, GD: Clinical investigators, served as scientific advisors. MTB, OK, HG: Critically reviewed the study proposals, collected data, provided and cared for study patients. MTB, AP, MA: Participated in writing or technical editing of the manuscript.

REFERENCES

1. The Global Cancer Observatory G. Breast Cancer. Source: Globocan 2018. World Heal Organ [Internet]. 2018; 876:2018-9. Available from: <http://gco.iarc.fr/today>
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin* 2019; **69**(1):7-34. doi: 10.3322/caac.21551.
3. Telli ML, Gradishar WJ, Ward JH. NCCN guidelines updates: Breast cancer. *J Natl Compr Canc Netw* 2019; doi: 10.6004/jccn.2019.5006.
4. Jones C, Lancaster R. Evolution of operative technique for mastectomy. *Surg Clin North Am* 2018; **98**(4):835-44. doi.org/10.1016/j.suc.2018.04.003
5. Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, *et al.* Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. *J Surg Oncol* 2010; **102**(2):111-8. doi: 10.1002/jso.21535

6. Donahue EJ. Sentinel node imaging and biopsy in breast cancer patients. *Am J Surg* 2001; **182(4)**:426-8. doi.org/10.1016/S0002-9610(01)00731-0
7. Valente SA, Levine GM, Silverstein MJ, Rayhanabad JA, Weng-Grumley JG, Ji L, et al. Accuracy of predicting axillary lymph node positivity by physical examination, mammography, ultrasonography, and magnetic resonance imaging. *Ann Surg Oncol* 2012; **19(6)**:1825-30. doi: 10.1245/s10434-011-2200-7.
8. Arriagada R, Le MG, Dunant A, Tubiana M, Contesso G. Twenty-five years of follow-up in patients with operable breast carcinoma: Correlation between clinicopathologic factors and the risk of death in each 5-year period. *Cancer* 2006; **106(4)**:743-50. doi: 10.1002/cncr.21659.
9. An YS, Lee DH, Yoon JK, Lee SJ, Kim TH, Kang DK, et al. Diagnostic performance of 18F-FDG PET/CT, ultra-sonography and MRI. *Nuklearmedizin* 2014; **53(03)**:89-94. doi: 10.3413/Nukmed-0605-13-06
10. Ergul N, Kadioglu H, Yildiz S, Yucel SB, Gucin Z, Erdogan EB, et al. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy. *Acta radiol* 2015; **56(8)**:917-23. doi: 10.1177/0284185114539786.
11. Panda SK, Goel A, Nayak V, Shaik Basha S, Pande PK, Kumar K. Can preoperative ultrasonography and mri replace sentinel lymph node biopsy in management of axilla in early breast cancer — A Prospective study from a tertiary cancer center. *Indian J Surg Oncol* 2019; **10(3)**:483-8. doi: 10.1007/s13193-019-00924-7.
12. Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, et al. Utility of 18F-fluoro-deoxyglucose emission tomography/ computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. *BMC Cancer* 2008; **8**:1-10. doi: 10.1186/1471-2407-8-165.
13. Grueneisen J, Nagarajah J, Buchbender C, Hoffmann O, Schaarschmidt BM, Poeppel T, et al. Positron emission tomography/magnetic resonance imaging for local tumor staging in patients with primary breast cancer: A comparison with positron emission tomography/computed tomography and magnetic resonance imaging. *Invest Radiol* 2015; **50(8)**:505-13. doi: 10.1097/RLI.0000000000000197.
14. Liang X, Yu J, Wen B, Xie J, Cai Q, Yang Q. MRI and FDG-PET/CT based assessment of axillary lymph node metastasis in early breast cancer: A meta-analysis. *Clin Radiol* 2017; **72(4)**:295-301. doi: 10.1016/j.crad.2016.12.001.
15. McDonough MD, DePeri ER, Mincey BA. The role of positron emission tomographic imaging in breast cancer. *Curr Oncol Rep* 2004; **6(1)**:62-8.
16. Lovrics PJ, Chen V, Coates G, Cornacchi SD, Goldsmith CH, Law C, et al. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. *Ann Surg Oncol* 2004; **11(9)**:846-53. doi: 10.1245/ASO.2004.11.033
17. Giuliano AE, Ballman K V., McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial. *JAMA - J Am Med Assoc* 2017; **318(10)**:918-26. doi: 10.1001/jama.2017.11470.
18. Liberale V, Rosso R, Arisio R, D'Alonzo M, Villasco A, Fuso L, et al. Axillary dissection in patients with preoperative positive nodal cytology: Genuine need or overtreatment? *Breast J* 2020; **26(2)**:168-75. doi: 10.1111/tbj.13479.
19. Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE, Hortobagyi GN, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. *Cancer* 1993; doi: 10.1002/1097-0142(19930615)71:12<3920::aid-cncr2820711220>3.0.co;2-n.
20. Kvistad KA, Rydland J, Smethurst HB, Lundgren S, Fjøsne HE, Haraldseth O. Axillary lymph node metastases in breast cancer: Preoperative detection with dynamic contrast-enhanced MRI. *Eur Radiol* 2000; **10(9)**:1464-71. doi: 10.1007/s003300000370.

•••••